Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $394,000.

  • Mereo BioPharma Group's Other Non-Current Assets fell 9.84% to $394,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $394,000, marking a year-over-year decrease of 9.84%. This contributed to the annual value of $378,000 for FY2024, which is 38.54% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Other Non-Current Assets stood at $394,000 for Q3 2025, which was down 1.99% from $402,000 recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Other Non-Current Assets ranged from a high of $615,000 in Q4 2023 and a low of $378,000 during Q4 2024.
  • For the 3-year period, Mereo BioPharma Group's Other Non-Current Assets averaged around $440,143, with its median value being $402,000 (2025).
  • Data for Mereo BioPharma Group's Other Non-Current Assets shows a maximum YoY tumbled of 38.54% (in 2024) over the last 5 years.
  • Mereo BioPharma Group's Other Non-Current Assets (Quarterly) stood at $615,000 in 2023, then crashed by 38.54% to $378,000 in 2024, then dropped by 9.84% to $394,000 in 2025.
  • Its Other Non-Current Assets stands at $394,000 for Q3 2025, versus $402,000 for Q2 2025 and $380,000 for Q1 2025.